185 related articles for article (PubMed ID: 33627056)
1. Dual-phase 68Ga-PSMA-11 PET/CT may increase the rate of detected lesions in prostate cancer patients.
Dadgar H; Seyedi Vafaee M; Norouzbeigi N; Jafari E; Gholamrezanezhad A; Assadi M
Urologia; 2021 Nov; 88(4):355-361. PubMed ID: 33627056
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. Early PET imaging with [68]Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence.
Uprimny C; Kroiss AS; Fritz J; Decristoforo C; Kendler D; von Guggenberg E; Nilica B; Maffey-Steffan J; di Santo G; Bektic J; Horninger W; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1647-1655. PubMed ID: 28589253
[TBL] [Abstract][Full Text] [Related]
4. (68)Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer.
Sachpekidis C; Eder M; Kopka K; Mier W; Hadaschik BA; Haberkorn U; Dimitrakopoulou-Strauss A
Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1288-99. PubMed ID: 26753602
[TBL] [Abstract][Full Text] [Related]
5. Early dynamic imaging in
Uprimny C; Kroiss AS; Decristoforo C; Fritz J; Warwitz B; Scarpa L; Roig LG; Kendler D; von Guggenberg E; Bektic J; Horninger W; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2017 May; 44(5):765-775. PubMed ID: 27900519
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of early imaging with
Özülker F
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2019; 38(2):100-105. PubMed ID: 30514659
[TBL] [Abstract][Full Text] [Related]
7. Impact of uptake time on image quality of [
van der Sar ECA; Viol SLM; Braat AJAT; van Rooij R; Lam MGEH; de Jong HWAM; de Keizer B
Med Phys; 2023 Dec; 50(12):7619-7628. PubMed ID: 37093883
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the diagnostic utility of 99mTc-PSMA scintigraphy versus 68Ga-PSMA-11 PET/CT in the detection of metastatic prostate cancer and dosimetry analysis: a gamma-camera-based alternate prostate-specific membrane antigen imaging modality.
Singh B; Sharma S; Bansal P; Hooda M; Singh H; Parihar AS; Kumar A; Watts A; Mohan R; Singh SK
Nucl Med Commun; 2021 May; 42(5):482-489. PubMed ID: 33395191
[TBL] [Abstract][Full Text] [Related]
9. Prospective Comparison of
Duan H; Song H; Davidzon GA; Moradi F; Liang T; Loening A; Vasanawala S; Iagaru A
J Nucl Med; 2024 Jun; 65(6):897-903. PubMed ID: 38664016
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Early Imaging and Imaging 60 min Post-Injection after Forced Diuresis with Furosemide in the Assessment of Local Recurrence in Prostate Cancer Patients with Biochemical Recurrence Referred for 68Ga-PSMA-11 PET/CT.
Bayerschmidt S; Uprimny C; Kroiss AS; Fritz J; Nilica B; Svirydenka H; Decristoforo C; von Guggenberg E; Horninger W; Virgolini IJ
Diagnostics (Basel); 2021 Jun; 11(7):. PubMed ID: 34208989
[TBL] [Abstract][Full Text] [Related]
11. Primary lymph-node staging with
Corona-Montes VE; González-Cuenca E; Fernández-Noyola G; Olarte-Casas MA; Bobadilla-Salazar D; Medrano-Urtecho HM; Asimakopoulos AD
Urol Oncol; 2021 Aug; 39(8):494.e1-494.e6. PubMed ID: 33223371
[TBL] [Abstract][Full Text] [Related]
12. 68Ga-PSMA-11 PET/CT derived quantitative volumetric tumor parameters for classification and evaluation of therapeutic response of bone metastases in prostate cancer patients.
Schmidkonz C; Cordes M; Goetz TI; Prante O; Kuwert T; Ritt P; Uder M; Wullich B; Goebell P; Bäuerle T
Ann Nucl Med; 2019 Oct; 33(10):766-775. PubMed ID: 31338731
[TBL] [Abstract][Full Text] [Related]
13. [Diagnostic performance of 68GA-PSMA PET/CTin patients with prostate cancer].
Veliev EI; Tomilov AA; Goncharuk DA; Bogdanov AB; Golubtsova EN
Urologiia; 2018 Jul; (3):105-110. PubMed ID: 30035428
[TBL] [Abstract][Full Text] [Related]
14. 99mTc-PSMA SPECT/CT Versus 68Ga-PSMA PET/CT in the Evaluation of Metastatic Prostate Cancer.
Fallahi B; Khademi N; Karamzade-Ziarati N; Fard-Esfahani A; Emami-Ardekani A; Farzanefar S; Eftekhari M; Beiki D
Clin Nucl Med; 2021 Feb; 46(2):e68-e74. PubMed ID: 33234922
[TBL] [Abstract][Full Text] [Related]
15. Optimal time-point for
Beheshti M; Paymani Z; Brilhante J; Geinitz H; Gehring D; Leopoldseder T; Wouters L; Pirich C; Loidl W; Langsteger W
Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1188-1196. PubMed ID: 29476228
[TBL] [Abstract][Full Text] [Related]
16.
Calais J; Ceci F; Eiber M; Hope TA; Hofman MS; Rischpler C; Bach-Gansmo T; Nanni C; Savir-Baruch B; Elashoff D; Grogan T; Dahlbom M; Slavik R; Gartmann J; Nguyen K; Lok V; Jadvar H; Kishan AU; Rettig MB; Reiter RE; Fendler WP; Czernin J
Lancet Oncol; 2019 Sep; 20(9):1286-1294. PubMed ID: 31375469
[TBL] [Abstract][Full Text] [Related]
17. A Multicenter Prospective Clinical Trial of
McCarthy M; Francis R; Tang C; Watts J; Campbell A
Int J Radiat Oncol Biol Phys; 2019 Jul; 104(4):801-808. PubMed ID: 30890448
[TBL] [Abstract][Full Text] [Related]
18. Multiphasic
Beheshti M; Manafi-Farid R; Geinitz H; Vali R; Loidl W; Mottaghy FM; Langsteger W
J Nucl Med; 2020 Oct; 61(10):1484-1490. PubMed ID: 32060214
[TBL] [Abstract][Full Text] [Related]
19. Combined Early and Late [
Hohberg M; Kobe C; Täger P; Hammes J; Schmidt M; Dietlein F; Wild M; Heidenreich A; Drzezga A; Dietlein M
Mol Imaging Biol; 2019 Jun; 21(3):558-566. PubMed ID: 30105521
[TBL] [Abstract][Full Text] [Related]
20.
Uprimny C; Kroiss AS; Decristoforo C; Fritz J; von Guggenberg E; Kendler D; Scarpa L; di Santo G; Roig LG; Maffey-Steffan J; Horninger W; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):941-949. PubMed ID: 28138747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]